Tesařová L, Simara P, Stejskal S, Koutná I
Centre for Biomedical Image Analysis, Faculty of Informatics, Masaryk University, Brno, Czech Republic.
Folia Biol (Praha). 2014;60 Suppl 1:90-4.
The generation of haematopoietic progenitors from human pluripotent stem cells (hPSCs) presents great promise for cell-replacement therapies. However, current protocols for haematopoietic differentiation of hPSCs suffer from low efficiency and functional defects in the derived cells. The technology is also limited by variable ability of hPSC lines to generate blood cells in vitro. To address this issue, methodologies for haematopoietic differentiation in feeder-free conditions were applied to available human embryonic stem cell (hESC) and human induced pluripotent stem cell (hiPSC) lines in this study. It was found that these cell lines did not generate haematopoietic progenitors to such an extent as did H1 and H9 hESC lines that were used for this purpose in the vast majority of relevant studies. These results suggest that for clinical application of blood cells derived from hPSCs, possibly from autologous hiPSCs, it is necessary to overcome the variability in the haematopoietic developmental potential of individual hPSC lines.
从人多能干细胞（hPSC）生成造血祖细胞为细胞替代疗法带来了巨大希望。然而，目前hPSC造血分化方案存在效率低下以及所衍生细胞功能缺陷的问题。该技术还受到hPSC系在体外生成血细胞能力差异的限制。为解决这一问题，本研究将无饲养层条件下的造血分化方法应用于现有的人类胚胎干细胞（hESC）系和人类诱导多能干细胞（hiPSC）系。结果发现，这些细胞系生成造血祖细胞的程度不及绝大多数相关研究中用于此目的的H1和H9 hESC系。这些结果表明，对于源自hPSC（可能源自自体hiPSC）的血细胞的临床应用，有必要克服各个hPSC系造血发育潜能的变异性。
